The global cervical cancer diagnostic market is witnessing steady growth due to the rising prevalence of cervical cancer, increasing awareness about early detection, and advancements in diagnostic technologies. Human papillomavirus (HPV) infection is the primary risk factor for cervical cancer, leading to a growing demand for HPV tests, Pap smears, and liquid-based cytology. The adoption of molecular diagnostics, AI-driven screening methods, and point-of-care testing is improving early detection rates and enhancing patient outcomes. Government initiatives and vaccination programs aimed at reducing cervical cancer incidence are further fueling market expansion.
Global Cervical Cancer Diagnostic Market is expected to reach USD 13.02 billion by 2030, with a growing CAGR of 6.9% during the forecast period 2023 to 2030.
To know more, visit https://www.databridgemarketresearch.com/reports/global-cervical-cancer-diagnostic-market
Below are the Top Cervical Cancer Diagnostic Companies with a Significant Market Share:
|
Rank
|
Company
|
Overview
|
Product Portfolio
|
Sales Geographical Coverage
|
Developments
|
|
1.
|
Siemens Healthcare GmbH
|
Siemens Healthineers is a global leader in cervical cancer diagnostics, offering advanced HPV DNA tests, liquid-based cytology (LBC), and imaging solutions for early detection. The company’s ADVIA Centaur and Atellica platforms provide high-throughput HPV screening and biomarker testing. Siemens also integrates AI-driven analytics to improve cervical cancer diagnosis and patient management.
|
|
North America, South America, Middle East and Africa, Asia-Pacific, and Europe
|
In August 2020, Siemens Healthcare GmbH agreed with Varian Medical Systems, Inc. With this acquisition, Siemens Healthcare has helped develop advanced solutions to treat cancer and strengthen its position in the healthcare industry.
|
|
2.
|
BD
|
BD is a pioneer in cervical cancer screening with its BD SurePath liquid-based cytology system and BD Onclarity HPV assay, which detects multiple high-risk HPV genotypes. The company focuses on automated screening solutions to enhance accuracy and efficiency in detecting precancerous and cancerous cervical lesions. BD’s innovations help improve early detection and patient outcomes.
|
|
North America, South America, Middle East and Africa, Asia-Pacific, and Europe
|
In June 2020, BD announced the acquisition of Straub Medical AG, a privately-held company. With this acquisition, the company has added the valuable expertise and experience of Straub Medical AG and expanded its product portfolio.
|
|
3.
|
F. Hoffmann-La Roche Ltd.
|
Roche is a major player in cervical cancer diagnostics, offering HPV DNA and biomarker-based tests for early detection and risk assessment. Its cobas® HPV test is widely used for primary screening, triage, and co-testing with Pap smears. Roche’s molecular diagnostic solutions provide high sensitivity and specificity, enabling early intervention in cervical cancer cases.
|
|
North America, Middle East and Africa, Asia-Pacific, and Europe
|
In May 2020, F. Hoffmann-La Roche Ltd acquired Stratos Genomics officially. With this acquisition, the company will also deal with the development of DNA-based sequencing for diagnostics use. This has enhanced the healthcare diagnosis segment of the company, thus leading to more revenue generation.
|
|
4.
|
Abbott
|
Abbott provides molecular and immunoassay-based diagnostic solutions for cervical cancer detection. The company’s RealTime High-Risk HPV assay helps identify high-risk HPV types associated with cervical cancer. Abbott also focuses on automated and high-throughput screening solutions, improving laboratory efficiency and accessibility to cervical cancer diagnostics worldwide.
|
|
Americas, Middle East and Africa, Asia-Pacific, and Europe
|
In November 2023, Abbott received U.S. Food and Drug Administration (FDA) approval for its Alinity m HR HPV assay, a molecular test designed for high-risk human papillomavirus (HPV) detection. This test identifies 14 high-risk HPV genotypes associated with cervical cancer, providing detailed genotyping information to assess a patient's risk accurately.
|
|
5.
|
Hologic, Inc.
|
Hologic is a global leader in women’s health diagnostics, offering advanced Pap testing, HPV screening, and cytology solutions. Its ThinPrep Pap test and Aptima HPV assays are widely used for detecting cervical precancerous and cancerous lesions. Hologic’s emphasis on early detection and automation helps healthcare providers improve cervical cancer screening programs.
|
|
North America, South America, Middle East and Africa, Asia-Pacific, and Europe
|
In February 2024, Hologic, Inc. achieved a significant milestone in cervical cancer diagnostics with the FDA clearance of its Genius™ Digital Diagnostics System. This system is the first and only FDA-cleared digital cytology platform that combines advanced volumetric imaging technology with deep-learning-based artificial intelligence (AI) to enhance the detection of pre-cancerous lesions and cervical cancer cells.
|
Conclusion
The global cervical cancer diagnostic market is expected to grow as technological innovations and government initiatives drive early detection and screening efforts. The integration of AI and molecular diagnostics is improving test accuracy, leading to better patient management and treatment outcomes. While challenges such as affordability and accessibility persist, ongoing research, awareness campaigns, and expanding healthcare infrastructure will continue to support market growth in the coming years.
